DAVID GUO: Open Payments
NPI 1629664131 · HONOLULU, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$870 in 21 payments from 9 companies in 2025. Trend: 2023 $143 · 2024 $1,265 · 2025 $870
Food & beverage: $736Education: $134
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $232 |
| Alkermes, Inc. | 2 | $145 |
| ABBVIE INC. | 5 | $125 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $68 |
| Janssen Pharmaceuticals, Inc | 2 | $60 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $51 |
| E.R. Squibb & Sons, L.L.C. | 1 | $32 |
| Lundbeck LLC | 1 | $31 |
Products named: VRAYLAR, FANAPT, ARISTADA, AUSTEDO XR, CAPLYTA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, COBENFY.
Industry payments across HI — which companies pay providers there.
